Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH (Non-Alcoholic Steatohepatitis) Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Online App Weight Loss Programs on Liver Health in Obese Adults

NCT05015491
View directory record Official record
Conditions
NASH, Fatty Liver, NAFLD, Weight Loss
Interventions
Noom Healthy Weight Program
Behavioral
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children

NCT02383485
View directory record Official record
Conditions
Overweight and Obesity, Non-alcoholic Fatty Liver Disease
Interventions
Exercise, After-school program
Behavioral
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 11 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 14, 2026, 9:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

NCT06354491
View directory record Official record
Conditions
NAFLD, NASH
Interventions
Magnetic Resonance Imaging (MRI), Ultrasound (US)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
10 Years to 14 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)

NCT00063635
View directory record Official record
Conditions
Fatty Liver
Interventions
Metformin, Vitamin E, Matching placebo
Drug · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 14, 2026, 9:24 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease

NCT04132440
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Physician
Interventions
Interview, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of an RBAC Supplement (BRM4) on NAFLD

NCT02568787
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
rice bran arabinoxylan compound (RBAC), Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 14, 2026, 9:24 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 14, 2026, 9:24 AM EDT
Withdrawn No phase listed Observational

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

NCT03980912
View directory record Official record
Conditions
NAFLD, NASH
Interventions
LiverFASt
Diagnostic Test
Lead sponsor
Fibronostics USA, Inc
Other
Eligibility
18 Years to 80 Years
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589
View directory record Official record
Conditions
HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

NCT04399538
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
PF-06865571, PF-05221304, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 14, 2026, 9:24 AM EDT
Withdrawn No phase listed Observational

Evaluation of Intestinal Microbiome in Obese Kids

NCT00816296
View directory record Official record
Conditions
Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Blood Draw, Stool collection, BodPod Measurement, Liver Ultrasound
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Not applicable Interventional

The Liver Health Study for Patients with NAFLD

NCT03151798
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions
Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
Behavioral · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
22 Years to 65 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 14, 2026, 9:24 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

NCT02933554
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions
Embospheres Microspheres
Device
Lead sponsor
Keith Pereira, MD:
Other
Eligibility
22 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 14, 2026, 9:24 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

NCT04383951
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
Dietary consult for participants in the ketogenic diet arm, Dietary consult for participants in the standard of care arm
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 14, 2026, 9:24 AM EDT
Recruiting Phase 3 Interventional

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

NCT07221227
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin alfa, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
74
States / cities
Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

NCT04521114
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Placebo, leronlimab 700 mg, leronlimab 350 mg
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Coronado, California • Maitland, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

NCT01975935
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 14, 2026, 9:24 AM EDT
Recruiting Phase 2 Interventional

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

NCT04501406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 14, 2026, 9:24 AM EDT
Recruiting Phase 1 Interventional

Bicalutamide Therapy in Young Women With NAFLD and PCOS

NCT05979389
View directory record Official record
Conditions
NAFLD, PCOS
Interventions
Bicalutamide 50 mg, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 14, 2026, 9:24 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

AGED Diagnostics Liver Disease Assessment

NCT06348563
View directory record Official record
Conditions
NASH With Fibrosis, NAFLD, Healthy
Interventions
AGED Multiple Target Assay in Healthy Controls, AGED Multiple Target Assay in NAFLD Participants, AGED Multiple Target Assay in Fibrosis Participants
Diagnostic Test
Lead sponsor
Active Genomes Expressed Diagnostics, Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 14, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

NCT02571192
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, 5.95 μCi RAD
Drug · Radiation
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 14, 2026, 9:24 AM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 14, 2026, 9:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis

NCT00930384
View directory record Official record
Conditions
Psoriasis, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 14, 2026, 9:24 AM EDT